Recombinant Human Elafin is produced by our mammalian expression system in human cells. The target protein is expressed with sequence (Ala23-Gln117) of Human PI3 fused with a 6His tag at the C-terminus.
Pureté
> 95 % as determined by reducing SDS-PAGE.
Stérilité
0.2 μm filtered
niveau d'endotoxine
Less than 0.1 ng/μg (1 IEU/μg) as determined by LAL test
It is not recommended to reconstitute to a concentration less than 100 μg/mL. Dissolve the lyophilized protein in ddH2O. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Buffer
Supplied as a 0.2 μm filtered solution of 20 mM TrisHCl, 150 mM NaCl, pH 7.5.
Conseil sur la manipulation
Always centrifuge tubes before opening. Do not mix by vortex or pipetting.
Stock
-80 °C
Stockage commentaire
Store at < -20°C, stable for 6 months after receipt. Please minimize freeze-thaw cycles.
Elafin is a secreted protein. Elafin consists of two domains: the transglutaminase substrate domain (cementoin moiety) and the elastase inhibitor domain. The transglutaminase substrate domain serves as an anchor to localize Elafin covalently to specific sites on extracellular matrix proteins. It is shown that Elafin can be used as a biomarker for graft versus host disease of the skin. Elafin is expressed in the skin during wound healing through activation of the epidermal growth factor receptor. Elafin may prevent elastase-mediated tissue proteolysis. Alternative Names: Elafin, Elastase-Specific Inhibitor, ESI, Peptidase Inhibitor 3, PI-3, Protease inhibitor WAP3, Skin-Derived Antileukoproteinase, SKALP, WAP Four-Disulfide Core Domain Protein 14, PI3, WAP3, WFDC14